136 related articles for article (PubMed ID: 17986648)
1. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
[TBL] [Abstract][Full Text] [Related]
2. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study.
Verrills NM; Liem NL; Liaw TY; Hood BD; Lock RB; Kavallaris M
Proteomics; 2006 Mar; 6(5):1681-94. PubMed ID: 16456880
[TBL] [Abstract][Full Text] [Related]
4. Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias--correlation to the expression of multidrug resistance proteins.
Fichtner I; Paal K; Borgmann A; Badiali L; Wurm R; Henze G
Anticancer Res; 2003; 23(3B):2657-64. PubMed ID: 12894554
[TBL] [Abstract][Full Text] [Related]
5. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
[TBL] [Abstract][Full Text] [Related]
7. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
9. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
10. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
11. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine.
Liang GW; Lu WL; Wu JW; Zhao JH; Hong HY; Long C; Li T; Zhang YT; Zhang H; Wang JC; Zhang X; Zhang Q
Fundam Clin Pharmacol; 2008 Aug; 22(4):429-37. PubMed ID: 18705753
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
14. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
15. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
[TBL] [Abstract][Full Text] [Related]
16. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
[TBL] [Abstract][Full Text] [Related]
17. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
18. Effects of cytoskeletal inhibitors on the accumulation of vincristine in a resistant human lung cancer cell line with high level of polymerized tubulin.
Chan MW; Chiang CD; Song EJ; Yang VC
Cancer Biochem Biophys; 1998 Nov; 16(4):347-63. PubMed ID: 9925282
[TBL] [Abstract][Full Text] [Related]
19. The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
Estes DA; Lovato DM; Khawaja HM; Winter SS; Larson RS
Br J Haematol; 2007 Oct; 139(1):20-30. PubMed ID: 17854304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
